GABLOFEN Drug Patent Profile

When do Gablofen patents expire, and when can generic versions of Gablofen launch?

Gablofen is a drug marketed by Piramal Critical and is included in one NDA.

The generic ingredient in GABLOFEN is baclofen. There is one drug master file entry for this compound. Sixty-three suppliers are listed for this compound. Additional details are available on the baclofen profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Gablofen

A generic version of GABLOFEN was approved as baclofen by IVAX SUB TEVA PHARMS on July 21^st, 1988.

Summary for GABLOFEN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	132
Clinical Trials:	4
Patent Applications:	4,978
Drug Prices:	Drug price information for GABLOFEN
What excipients (inactive ingredients) are in GABLOFEN?	GABLOFEN excipients list
DailyMed Link:	GABLOFEN at DailyMed

See drug prices for GABLOFEN

Recent Clinical Trials for GABLOFEN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tanta University	N/A
Pennsylvania Department of Health	Phase 2
National Institutes of Health (NIH)	Phase 2

See all GABLOFEN clinical trials

Pharmacology for GABLOFEN

Drug Class	gamma-Aminobutyric Acid-ergic Agonist
Mechanism of Action	GABA A Agonists GABA B Agonists

US Patents and Regulatory Information for GABLOFEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Piramal Critical	GABLOFEN	baclofen	INJECTABLE;INTRATHECAL	022462-001	Nov 19, 2010	AP	RX	Yes	Yes
Piramal Critical	GABLOFEN	baclofen	INJECTABLE;INTRATHECAL	022462-003	Nov 19, 2010	AP	RX	Yes	Yes
Piramal Critical	GABLOFEN	baclofen	INJECTABLE;INTRATHECAL	022462-002	Nov 19, 2010	AP	RX	Yes	Yes
Piramal Critical	GABLOFEN	baclofen	INJECTABLE;INTRATHECAL	022462-004	Jun 22, 2012	AP	RX	Yes	Yes

GABLOFEN Market Dynamics, Financial Trajectory, Competition, and Patent Risk

Last updated: August 15, 2026

GABLOFEN is a branded generic formulation of intrathecal baclofen manufactured by Piramal Critical Care. Its market is driven by long-term treatment of severe spasticity, implanted pump utilization, hospital purchasing, and specialist prescribing rather than broad retail demand. Product-specific revenue is not publicly reported, so GABLOFEN’s financial trajectory must be assessed through market structure, FDA status, hospital-channel economics, and Piramal’s disclosed Critical Care performance.

What is GABLOFEN and how is it used?

GABLOFEN is baclofen injection administered intrathecally through an implanted infusion pump. The product is used for severe spasticity in patients who do not respond adequately to oral baclofen or who cannot tolerate oral therapy. The FDA label identifies cerebral-origin and spinal-origin spasticity as key treatment populations, including patients with multiple sclerosis, spinal cord injury, traumatic brain injury, and cerebral palsy.[1]

GABLOFEN is supplied in preservative-free, single-dose containers at multiple concentrations. The concentration is selected according to pump requirements, patient response, and the need to limit refill frequency.

Product characteristic	GABLOFEN position
Active ingredient	Baclofen
Route	Intrathecal
Administration	Implanted infusion pump
Primary use	Severe chronic spasticity
Manufacturer	Piramal Critical Care
Product type	Branded generic
Retail model	Limited retail exposure; primarily institutional and specialty care
Regulatory pathway	FDA-approved injectable product
Biosimilar status	Not applicable
Primary competitors	Lioresal Intrathecal and other baclofen injection products

Intrathecal baclofen therapy is a specialist market. Neurosurgeons, neurologists, physical-medicine physicians, rehabilitation centers, and hospital systems influence product selection. The drug is generally purchased as part of a broader pump-treatment service that includes implantation, programming, refilling, monitoring, and complication management.

How large is the GABLOFEN market?

The addressable market is narrower than the overall baclofen market because GABLOFEN competes only in intrathecal administration. Oral baclofen remains the first-line pharmacologic treatment for many patients. Intrathecal therapy is reserved for severe cases where the clinical benefit justifies surgery and recurring pump maintenance.

Market demand has four structural drivers:

1. The installed base of intrathecal pumps.
2. The prevalence of severe spasticity caused by neurologic disease or injury.
3. Refill and replacement cycles for implanted pumps.
4. Hospital and specialty-pharmacy purchasing decisions.

The principal constraint is the invasive nature of treatment. Pump implantation requires surgery, while long-term therapy requires regular refills and clinical monitoring. Device infection, catheter failure, overdose, withdrawal, and dosing errors also create clinical and operational risks.[1]

GABLOFEN demand is therefore relatively defensive after a patient has entered pump therapy. A patient receiving chronic intrathecal baclofen generally requires continuing drug supply, although the product can be exposed to hospital formulary changes, generic substitution, and pump-system economics.

What is the financial trajectory for GABLOFEN?

Piramal does not separately disclose GABLOFEN net sales, gross margin, unit volume, or operating profit. The product is reported within the company’s broader Critical Care business rather than as a standalone financial segment. Public filings therefore do not establish a product-specific revenue trend.[2]

The likely financial trajectory has four phases:

Period	Financial dynamic	Effect on GABLOFEN
Launch and adoption	Product differentiation and specialist conversion	Higher pricing potential
Market expansion	Growth in pump utilization and hospital awareness	Volume-driven growth
Generic normalization	Competition and contracting pressure	Lower unit price
Mature market	Stable refill demand and recurring treatment	Volume stability, pricing pressure

GABLOFEN’s economics differ from those of an ordinary injectable generic. The product is not a high-volume emergency injectable and does not rely on broad retail dispensing. Its commercial value comes from recurring use in a specialized treatment pathway, limited prescriber concentration, and the operational cost of switching products.

The main financial risks are:

• Price concessions to group purchasing organizations.
• Hospital conversion to lower-cost baclofen injection products.
• Reduced elective pump implantation.
• Lower procedural volume during hospital-capacity constraints.
• Supply interruptions affecting sterile injectable products.
• Concentration of demand among a limited number of specialty centers.
• Contract losses that can reduce volume quickly.

The main financial supports are:

• Recurring refill demand from existing pump patients.
• High switching friction after treatment initiation.
• The need for multiple concentrations.
• Limited substitution from oral baclofen in patients already dependent on intrathecal therapy.
• Clinical familiarity among pump-management centers.
• Potential value from reliable supply rather than premium branding.

Piramal’s broader Critical Care platform includes specialty injectables and products sold through hospitals and acute-care channels. Company disclosures describe the business at segment level, but they do not isolate GABLOFEN’s contribution.[2][3]

What is the FDA regulatory status of GABLOFEN?

GABLOFEN is FDA-approved for intrathecal use in patients with severe spasticity. Its label includes dosing, screening, pump administration, overdose management, withdrawal warnings, and concentration-specific instructions.[1]

The regulatory profile is mature. The principal regulatory risks are manufacturing compliance, sterile-product quality, labeling, pharmacovigilance, and supply continuity rather than clinical-development risk.

Key FDA considerations

GABLOFEN is subject to heightened operational requirements because it is:

• A sterile injectable product.
• Administered into the intrathecal space.
• Used with an implanted drug-delivery system.
• Associated with potentially severe overdose and withdrawal consequences.
• Distributed through hospitals, specialty providers, and pump clinics.

The FDA label warns that abrupt discontinuation can cause high fever, altered mental status, exaggerated rebound spasticity, muscle rigidity, rhabdomyolysis, multisystem organ failure, and death.[1] These risks increase the importance of uninterrupted supply and controlled pump management.

What is the Orange Book status of GABLOFEN?

GABLOFEN is not protected by a conventional new-molecular-entity exclusivity period because baclofen is an established active ingredient. Its commercial protection is based primarily on product approval, formulation and presentation execution, manufacturing reliability, customer relationships, and any applicable regulatory exclusivity or intellectual-property rights.

The Orange Book position should be distinguished from the broader baclofen market:

Issue	GABLOFEN implication
New chemical entity exclusivity	Not applicable to baclofen
Orphan-drug exclusivity	Not a principal commercial protection identified for GABLOFEN
Pediatric exclusivity	No product-specific basis identified in public materials
Patent protection	No widely recognized blocking patent estate comparable to a novel drug
ANDA competition	Potentially available where a qualifying reference product and approval pathway exist
Biosimilar pathway	Not applicable

The FDA Orange Book lists approved drug products and, where applicable, patent and exclusivity information. For a mature baclofen injection product, the practical competitive question is whether other manufacturers can obtain approval and qualify for institutional substitution, not whether a long patent term protects the molecule.[4]

What patents protect GABLOFEN?

GABLOFEN does not appear to have a patent estate comparable to a recently launched specialty drug. Baclofen was discovered and commercialized decades ago, and core composition-of-matter protection has expired.

Potentially relevant intellectual-property categories include:

Formulation patents

Formulation protection could cover concentration, excipient selection, stability, container closure, or preservative-free presentation. These rights would generally have narrower commercial scope than a composition-of-matter patent and may not prevent approval of a technically different baclofen injection.

Device and pump patents

The intrathecal pump, catheter, reservoir, refill system, and programming technology may be protected by device patents held by pump manufacturers. These rights are separate from GABLOFEN’s drug rights and do not necessarily block competing baclofen injections.

Manufacturing know-how

Sterile compounding, container filling, stability control, particulate control, and supply-chain qualification can create practical barriers even where patent protection is weak. These barriers are especially relevant for a drug administered intrathecally.

Method-of-use patents

The underlying use of baclofen to treat spasticity is mature. Broad method-of-use protection is unlikely to provide meaningful exclusion in the current market. Any narrower method claims would need to address a specific patient population, dosing method, delivery protocol, or pump-related use.

When does GABLOFEN lose exclusivity?

GABLOFEN has no identifiable upcoming loss-of-exclusivity event comparable to the expiry of a branded small-molecule drug patent. The relevant commercial risk is continuing generic competition and price erosion rather than a single patent cliff.

A competitor can challenge the product through several routes:

• FDA approval of another baclofen injection.
• Hospital formulary conversion.
• Contracting with group purchasing organizations.
• Private-label or distributor relationships.
• Product substitution in pump clinics.
• Pricing reductions by existing suppliers.

Paragraph IV litigation is not the central risk presently associated with GABLOFEN. A Paragraph IV filing would require an ANDA applicant to challenge listed patents for the relevant reference product. The commercial importance of such litigation depends on whether enforceable patents are listed and whether the proposed generic differs in concentration, packaging, or formulation. The publicly visible market structure does not indicate a major active patent dispute that would create a near-term, product-specific launch event.

Which companies compete with GABLOFEN?

The competitive landscape includes the originator product, generic baclofen injection suppliers, pump manufacturers, and alternative therapies.

Competitor category	Examples	Competitive effect
Originator intrathecal baclofen	Lioresal Intrathecal	Clinical reference and brand recognition
Generic baclofen injection	Multiple injectable suppliers, subject to FDA approvals and availability	Price pressure
Pump manufacturers	Medtronic and other device suppliers	Control access to pump ecosystem and service relationships
Oral antispasticity drugs	Oral baclofen, tizanidine, dantrolene and others	Reduce progression to pump therapy
Focal treatments	Botulinum toxin and nerve-targeted interventions	Substitute in selected patients
Nonpharmacologic therapy	Rehabilitation and physical therapy	Adjunctive or alternative treatment

GABLOFEN’s strongest commercial differentiation is likely operational rather than molecular. Pump centers value dependable supply, predictable concentration availability, compatible packaging, responsive customer service, and low disruption during patient refills.

How does GABLOFEN compare with Lioresal Intrathecal?

Lioresal Intrathecal is the originator reference product, while GABLOFEN competes as a lower-cost or alternative baclofen injection. Both products serve the same broad clinical pathway.

Factor	GABLOFEN	Lioresal Intrathecal
Active ingredient	Baclofen	Baclofen
Administration	Intrathecal pump	Intrathecal pump
Clinical role	Severe spasticity	Severe spasticity
Brand position	Branded generic	Originator brand
Patent advantage	Limited	Legacy product rights largely mature
Pricing position	Generally positioned for competition	Potential brand premium
Switching barrier	Pump-center protocols and clinician preference	Established clinical familiarity
Main risk	Generic price erosion and contracting	Loss of share to lower-cost alternatives

Clinical interchangeability may depend on the specific product, concentration, container, pump protocol, institutional policy, and physician judgment. A hospital can regard products as therapeutically similar while still requiring separate purchasing, stocking, and operational review.

What generic launch risks exist for GABLOFEN?

The risk of new generic entry is moderate from an intellectual-property perspective and higher from a commercial perspective if additional manufacturers secure FDA approval and reliable supply.

The key barriers are:

• Demonstrating injectable quality and sterility.
• Establishing stability across concentrations and packaging.
• Meeting FDA manufacturing requirements.
• Obtaining hospital formulary acceptance.
• Building relationships with pump clinics.
• Maintaining supply across a small but clinically sensitive market.
• Competing in contracts where price is heavily weighted.

A new entrant could pressure GABLOFEN pricing without immediately taking most volume. Pump centers may retain multiple suppliers to reduce shortage risk. In that setting, dependable supply can protect share even when the product lacks strong patent protection.

What licensing deals affect GABLOFEN?

No major public licensing transaction appears to define GABLOFEN’s current market position. Piramal’s ownership and commercialization of the product are more relevant than an external royalty structure disclosed for GABLOFEN.

Licensing risk is limited compared with products dependent on a third-party platform or patented delivery technology. The main commercial dependencies are manufacturing capacity, distribution, hospital contracting, and pump-center relationships.

What is the geographic coverage of GABLOFEN?

GABLOFEN is primarily a U.S. product in publicly visible commercial materials. Its market is concentrated in U.S. hospitals, specialty clinics, rehabilitation centers, and physician practices that manage implanted intrathecal pumps.

Geographic expansion is constrained by:

• Country-specific approvals.
• Different hospital procurement systems.
• Local reimbursement rules.
• Product-registration requirements.
• Pump compatibility standards.
• Sterile injectable manufacturing and distribution requirements.

The product’s addressable geography is therefore narrower than that of an oral baclofen product.

How strong is the GABLOFEN patent estate?

GABLOFEN’s patent strength is weak to moderate as a standalone drug asset. The molecule is old, broad therapeutic use is established, and the product does not appear to rely on a long-duration composition patent. Its practical defensibility is stronger than its patent position because the market has clinical, procedural, and supply-chain barriers.

Protection layer	Relative strength
Active ingredient patent	Weak or expired
Broad method-of-use rights	Weak
Product-specific formulation rights	Potentially narrow
Pump and delivery technology	Controlled mainly by device companies
Manufacturing know-how	Moderate practical protection
Hospital relationships	Moderate commercial protection
Patient switching friction	Moderate to strong
Regulatory exclusivity	Limited

What is the outlook for GABLOFEN revenue?

The most likely outlook is mature, recurring revenue with modest volume growth and persistent pricing pressure. Revenue can remain durable if the U.S. intrathecal pump population expands and Piramal maintains reliable supply. Margin performance will depend more on manufacturing efficiency and hospital contracting than on patent pricing power.

Upside factors include:

• Growth in the treated pump population.
• Increased adoption of intrathecal therapy in severe spasticity.
• Product availability across multiple concentrations.
• Supply shortages affecting competitors.
• Retention of major hospital and specialty-clinic contracts.

Downside factors include:

• New injectable baclofen entrants.
• Lower hospital procedure volumes.
• Pricing pressure from group purchasing organizations.
• Pump replacement delays.
• Manufacturing observations or recalls.
• Greater use of non-pump treatments in selected patients.

Key Takeaways

• GABLOFEN is a mature intrathecal baclofen product marketed by Piramal Critical Care.
• Its demand comes from implanted-pump patients with severe chronic spasticity.
• Product-specific revenue and profit are not separately disclosed by Piramal.
• The financial profile is recurring but exposed to hospital contracting and generic price erosion.
• GABLOFEN has limited apparent patent protection compared with newer specialty drugs.
• Biosimilar risk is not applicable because GABLOFEN is a small-molecule injectable, not a biologic.
• Paragraph IV litigation is not the primary visible competitive threat.
• The strongest defenses are supply reliability, sterile-manufacturing capability, pump-center relationships, and patient-switching friction.
• Lioresal Intrathecal remains the principal branded benchmark, while other baclofen injections create generic pricing pressure.
• The most probable commercial trajectory is stable or modestly growing volume with constrained pricing.

FAQs

Is GABLOFEN a generic drug?

GABLOFEN is a branded generic baclofen injection. It uses an established active ingredient and competes with the originator Lioresal Intrathecal and other baclofen injection products.

Is GABLOFEN covered by Medicare?

Coverage depends on the treatment setting, pump-related billing, Medicare contractor policy, and whether the product is supplied through a physician office, hospital outpatient department, or other provider. The drug is generally reimbursed within the broader intrathecal pump treatment pathway rather than through ordinary retail pharmacy dispensing.

Can GABLOFEN be substituted for Lioresal Intrathecal?

Substitution depends on product approval, concentration, pump requirements, institutional policy, and physician judgment. Therapeutic similarity does not automatically eliminate operational review for an implanted-pump product.

Does GABLOFEN have orphan-drug exclusivity?

GABLOFEN’s commercial position is not principally based on orphan-drug exclusivity. Its market protection comes from product approval, specialist use, supply capability, and established pump-center relationships.

What would cause a sharp decline in GABLOFEN sales?

The most likely causes would be loss of hospital contracts, new low-priced baclofen injection competitors, manufacturing disruption, reduced intrathecal pump procedures, or a safety or quality event affecting institutional confidence.

References

1. U.S. Food and Drug Administration. (2020). Gablofen (baclofen injection) prescribing information. Piramal Critical Care, Inc.

2. Piramal Enterprises Limited. (2024). Annual report 2023-2024. Piramal Enterprises Limited.

3. Piramal Pharma Limited. (2024). Annual report 2023-2024. Piramal Pharma Limited.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

DrugChatter Q&A for GABLOFEN

Gablofen?